Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Regulus (RGLS – Research Report) and keeping the price target at $10.00.
Ram Selvaraju has given his Buy rating due to a combination of factors including the promising interim results from Regulus’s ongoing Phase 1b study of farabursen in treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study’s Cohort 4 showed a positive mechanistic dose response and a significant reduction in kidney volume growth, indicating potential efficacy. Furthermore, the safety profile of farabursen was favorable, with the drug being well tolerated among participants.
Additionally, Regulus’s alignment with the FDA on the Phase 3 trial design, including the possibility of accelerated approval, strengthens the investment case. The company’s financial position, with a cash runway extending into early 2026, provides a solid foundation for ongoing operations and future developments. These factors collectively support the Buy rating, with a price target of $10.
Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Vanda, and Emergent Biosolutions. According to TipRanks, Selvaraju has an average return of 3.1% and a 38.31% success rate on recommended stocks.